Validation验证

How claims are tested: benchmarks, baselines, challenges and critiques.如何检验结论:基准、基线、挑战赛与批评。

Validation验证Review pending待审阅v0.1.0

Validating virtual cells: benchmarks, baselines and critiques虚拟细胞的验证:基准、基线与批评

Validation currently relies on benchmarks and challenges. Several independent studies report that deep perturbation models do not yet reliably beat simple linear baselines; clinical validation of virtual cells in neuro-oncology has not been reported in the library.目前的验证主要依靠基准与挑战赛。多项独立研究报告深度扰动模型尚不能稳定超越简单线性基线;文献库中尚无神经肿瘤领域虚拟细胞的临床验证报告。

Key evidence:关键证据: VC0048 VC0049 VC0050 VC0052 · 13 items cited共引用 13 条

Validation验证Review pending待审阅v0.1.0

Do Neftel-style GBM state calls replicate across platforms? A GlioState re-analysis (draft)Neftel 式 GBM 状态判定能否跨平台复现?GlioState 再分析(初稿)

In a GlioState re-analysis of public data (GSE131928), tumor-level state composition replicated moderately across Smart-seq2 and 10X (Spearman ρ=0.82 over 24 tumor×state values in 6 shared tumors; dominant state matched in 4 of 6), and a classifier using no signature genes recovered signature-based state calls on held-out 10X cells with balanced accuracy 0.75 (chance 0.25; single-marker baseline 0.53). This tests the reproducibility of state definitions only; it is not a test of any therapy-response or virtual-cell model, and the labels are not ground truth.在 GlioState 对公开数据(GSE131928)的再分析中,肿瘤水平的状态构成在 Smart-seq2 与 10X 之间中等程度复现(6 个共有肿瘤、24 个肿瘤×状态值的 Spearman ρ=0.82;优势状态 6 例中 4 例一致);不使用任何特征基因的分类器在留出的 10X 细胞上还原了基于特征基因的状态判定,平衡准确率 0.75(随机水平 0.25;单标志基因基线 0.53)。这只检验状态定义的可重复性,并非对任何治疗反应或虚拟细胞模型的检验,且标签不是金标准。

Key evidence:关键证据: VC0059 VC0060 VC0069 VC0092 · preprint · 预印本 · 8 items cited共引用 8 条

Linked evidence关联证据